Surgery Today

, Volume 40, Issue 9, pp 793–808 | Cite as

Immunosuppression following surgical and traumatic injury

  • Fumio Kimura
  • Hiroaki Shimizu
  • Hiroyuki Yoshidome
  • Masayuki Ohtsuka
  • Masaru Miyazaki
Review Article

Abstract

Severe sepsis and organ failure are still the major causes of postoperative morbidity and mortality after major hepatobiliary pancreatic surgery. Despite recent progress in understanding the immune conditions of abdominal sepsis, the postoperative incidence of septic complications after major visceral surgery remains high. This review focuses on the clinical and immunological parameters that determine the risk of the development and lethal outcome of postoperative septic complication following major surgery and trauma. A review of the literature indicates that surgical and traumatic injury profoundly affects the innate and adaptive immune responses, and that a marked suppression in cell-mediated immunity following an excessive inflammatory response appears to be responsible for the increased susceptibility to subsequent sepsis. The innate and adaptive immune responses are initiated and modulated by pathogen-associated molecular-pattern molecules and by damage-associated molecular-pattern molecules through the pattern-recognition receptors. Suppression of cell-mediated immunity may be caused by multifaceted cytokine/inhibitor profiles in the circulation and other compartments of the host, excessive activation and dysregulated recruitment of polymorphonuclear neutrophils, induction of alternatively activated or regulatory macrophages that have anti-inflammatory properties, a shift in the T-helper (Th)1/Th2 balance toward Th2, appearance of regulatory T cells, which are potent suppressors of the innate and adaptive immune system, and lymphocyte apoptosis in patients with sepsis. Recent basic and clinical studies have elucidated the functional effects of surgical and traumatic injury on the immune system. The research studies of interest may in future aid in the selection of appropriate therapeutic protocols.

Key words

Surgery Trauma Sepsis Organ failure Pattern-recognition receptors Polymorphonuclear neutrophils Monocytes/macrophages T lymphocytes 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Dixon E, Vollmer CM Jr, Sahajpal A, Cattral M, Grant D, Doig C, et al. An aggressive surgical approach leads to improved survival in patients with gallbladder cancer: a 12-year study at a North American Center. Ann Surg 2005;241:385–394.PubMedCrossRefGoogle Scholar
  2. 2.
    Shigeta H, Nagino M, Kamiya J, Uesaka K, Sano T, Yamamoto H, et al. Bacteremia after hepatectomy: an analysis of a singlecenter, 10-year experience with 407 patients. Langenbecks Arch Surg 2002;387:117–124.PubMedCrossRefGoogle Scholar
  3. 3.
    Schmidt CM, Powell ES, Yiannoutsos CT, Howard TJ, Wiebke EA, Wiesenauer CA, et al. Pancreaticoduodenectomy: a 20-year experience in 516 patients. Arch Surg 2004;139:718–725.PubMedCrossRefGoogle Scholar
  4. 4.
    Yeo CJ, Cameron JL, Lillemoe KD, Sohn TA, Campbell KA, Sauter PK, et al. Pancreaticoduodenectomy with or without distal gastrectomy and extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma, part 2: randomized controlled trial evaluating survival, morbidity, and mortality. Ann Surg 2002;236:355–366.PubMedCrossRefGoogle Scholar
  5. 5.
    Busquets J, Fabregat J, Borobia FG, Jorba R, Valls C, Serrano T, et al. Organ-preserving surgery for benign lesions and low-grade malignancies of the pancreatic head: a matched case-control study. Surg Today 2010;40:125–131.PubMedCrossRefGoogle Scholar
  6. 6.
    Angele MK, Chaudry IH. Surgical trauma and immunosuppression: pathophysiology and potential immunomodulatory approaches. Langenbecks Arch Surg 2005;390:333–341.PubMedCrossRefGoogle Scholar
  7. 7.
    Ni Choileain N, Redmond HP. Cell response to surgery. Arch Surg 2006;141:1132–1140.PubMedCrossRefGoogle Scholar
  8. 8.
    Ni Choileain N, Redmond HP. The immunological consequences of injury. Surgeon 2006;4:23–31.PubMedCrossRefGoogle Scholar
  9. 9.
    Lenz A, Franklin GA, Cheadle WG. Systemic inflammation after trauma. Injury 2007;38:1336–1345.PubMedCrossRefGoogle Scholar
  10. 10.
    Bone RC. Immunologic dissonance: a continuing evolution in our understanding of the systemic inflammatory response syndrome (SIRS) and the multiple organ dysfunction syndrome (MODS). Ann Intern Med 1996;125:680–687.PubMedGoogle Scholar
  11. 11.
    Moore FA, Moore EE. Evolving concepts in the pathogenesis of postinjury multiple organ failure. Surg Clin North Am 1995;75:257–277.PubMedGoogle Scholar
  12. 12.
    Tschoeke SK, Hellmuth M, Hostmann A, Ertel W, Oberholzer A. The early second hit in trauma management augments the proinflammatory immune response to multiple injuries. J Trauma 2007;62:1396–1403.PubMedCrossRefGoogle Scholar
  13. 13.
    Biffl WL, Moore EE, Moore FA, Peterson VM. Interleukin-6 in the injured patient. Marker of injury or mediator of inflammation? Ann Surg 1996;224:647–664.PubMedCrossRefGoogle Scholar
  14. 14.
    Baigrie RJ, Lamont PM, Kwiatkowski D, Dallman MJ, Morris PJ. Systemic cytokine response after major surgery. Br J Surg 1992;79:757–760.PubMedCrossRefGoogle Scholar
  15. 15.
    Gale LM, McColl SR. Chemokines: extracellular messengers for all occasions? Bioessays 1999;21:17–28.PubMedCrossRefGoogle Scholar
  16. 16.
    Strüber M, Cremer JT, Gohrbandt B, Hagl C, Jankowski M, Völker B, et al. Human cytokine responses to coronary artery bypass grafting with and without cardiopulmonary bypass. Ann Thorac Surg 1999;68:1330–1335.PubMedCrossRefGoogle Scholar
  17. 17.
    Lehmann AK, Halstensen A, Sørnes S, Røkke O, Waage A. High levels of interleukin 10 in serum are associated with fatality in meningococcal disease. Infect Immun 1995;63:2109–2112.PubMedGoogle Scholar
  18. 18.
    Marchant A, Alegre ML, Hakim A, Piérard G, Marécaux G, Friedman G, et al. Clinical and biological significance of interleukin-10 plasma levels in patients with septic shock. J Clin Immunol 1995;15:266–273.PubMedCrossRefGoogle Scholar
  19. 19.
    Howard M, Muchamuel T, Andrade S, Menon S. Interleukin 10 protects mice from lethal endotoxemia. J Exp Med 1993;177:1205–1208.PubMedCrossRefGoogle Scholar
  20. 20.
    Florquin S, Amraoui Z, Abramowicz D, Goldman M. Systemic release and protective role of IL-10 in staphylococcal enterotoxin B-induced shock in mice. J Immunol 1994;153:2618–2623.PubMedGoogle Scholar
  21. 21.
    DiPiro JT, Howdieshell TR, Goddard JK, Callaway DB, Hamilton RG, Mansberger AR Jr. Association of interleukin-4 plasma levels with traumatic injury and clinical course. Arch Surg 1995;130:1159–1162.PubMedGoogle Scholar
  22. 22.
    Wanidworanun C, Strober W. Predominant role of tumor necrosis factor-alpha in human monocyte IL-10 synthesis. J Immunol 1993;151:6853–6861.PubMedGoogle Scholar
  23. 23.
    Riedemann NC, Guo RF, Ward PA. Novel strategies for the treatment of sepsis. Nat Med 2003;9:517–524.PubMedCrossRefGoogle Scholar
  24. 24.
    Offner PJ, Moore EE, Ciesla D. The adrenal response after severe trauma. Am J Surg 2002;184:649–653.PubMedCrossRefGoogle Scholar
  25. 25.
    Keh D, Boehnke T, Weber-Cartens S, Schulz C, Ahlers O, Bercker S, et al. Immunologic and hemodynamic effects of “low-dose” hydrocortisone in septic shock: a double-blind, randomized, placebo-controlled, crossover study. Am J Respir Crit Care Med 2003;167:512–520.PubMedCrossRefGoogle Scholar
  26. 26.
    Roger T, Glauser MP, Calandra T. Macrophage migration inhibitory factor (MIF) modulates innate immune responses induced by endotoxin and Gram-negative bacteria. J Endotoxin Res 2001;7:456–460.PubMedGoogle Scholar
  27. 27.
    Kain ZN, Zimolo Z, Heninger G. Leptin and the perioperative neuroendocrinological stress response. J Clin Endocrinol Metab 1999;84:2438–2442.PubMedCrossRefGoogle Scholar
  28. 28.
    Sánchez-Margalet V, Martín-Romero C, Santos-Alvarez J, Goberna R, Najib S, Gonzalez-Yanes C. Role of leptin as an immunomodulator of blood mononuclear cells: mechanisms of action. Clin Exp Immunol 2003;133:11–19.PubMedCrossRefGoogle Scholar
  29. 29.
    Kimura F, Shimizu H, Yoshidome H, Ohtsuka M, Kato A, Yoshitomi H, et al. Circulating cytokines, chemokines, and stress hormones are increased in patients with organ dysfunction following liver resection. J Surg Res 2006;133:102–112.PubMedCrossRefGoogle Scholar
  30. 30.
    Kimura F, Miyazaki M, Suwa T, Sugiura T, Shinoda T, Itoh H, et al. Plasma concentration of cytokine antagonists in patients with infection following liver resection. Br J Surg 1998;85:1631–1635.PubMedCrossRefGoogle Scholar
  31. 31.
    Osuchowski MF, Welch K, Siddiqui J, Remick DG. Circulating cytokine/inhibitor profiles reshape the understanding of the SIRS/CARS continuum in sepsis and predict mortality. J Immunol 2006;177:1967–1974.PubMedGoogle Scholar
  32. 32.
    Martinon F, Tschopp J. NLRs join TLRs as innate sensors of pathogens. Trends Immunol 2005;26:447–454.PubMedCrossRefGoogle Scholar
  33. 33.
    Liew FY, Xu D, Brint EK, O’Neill LA. Negative regulation of toll-like receptor-mediated immune responses. Nat Rev Immunol 2005;5:446–458.PubMedCrossRefGoogle Scholar
  34. 34.
    Lamkanfi M, Kanneganti TD, Franchi L, Nunez G. Caspase-1 inflammasomes in infection and inflammation. J Leukoc Biol 2007;82:220–225.PubMedCrossRefGoogle Scholar
  35. 35.
    Kawai T, Akira S. Innate immune recognition of viral infection. Nat Immunol 2006;7:131–137.PubMedCrossRefGoogle Scholar
  36. 36.
    Härter L, Mica L, Stocker R, Trentz O, Keel M. Increased expression of toll-like receptor-2 and -4 on leukocytes from patients with sepsis. Shock 2004;22:403–409.PubMedCrossRefGoogle Scholar
  37. 37.
    Shalhub S, Junker CE, Imahara SD, Mindrinos MN, Dissanaike S, O’Keefe GE. Variation in the TLR4 gene influences the risk of organ failure and shock posttrauma: a cohort study. J Trauma 2009;66:115–122.PubMedCrossRefGoogle Scholar
  38. 38.
    Carneiro LA, Magalhaes JG, Tattoli I, Philpott DJ, Travassos LH. Nod-like proteins in inflammation and disease. J Pathol 2008;214:136–148.PubMedCrossRefGoogle Scholar
  39. 39.
    Martinon F. Orchestration of pathogen recognition by inflammasome diversity: Variations on a common theme. Eur J Immunol 2007;37:3003–3006.PubMedCrossRefGoogle Scholar
  40. 40.
    Sutterwala FS, Ogura Y, Flavell RA. The inflammasome in pathogen recognition and inflammation. J Leukoc Biol 2007;82:259–264.PubMedCrossRefGoogle Scholar
  41. 41.
    Podolsky DK. Inflammatory bowel disease. N Engl J Med 2002;347:417–429.PubMedCrossRefGoogle Scholar
  42. 42.
    Fahy RJ, Exline MC, Gavrilin MA, Bhatt NY, Besecker BY, Sarkar A, et al. Inflammasome mRNA expression in human monocytes during early septic shock. Am J Respir Crit Care Med 2008;177:983–988.PubMedCrossRefGoogle Scholar
  43. 43.
    Rubartelli A, Lotze MT. Inside, outside, upside down: damageassociated molecular-pattern molecules (DAMPs) and redox. Trends Immunol 2007;28:429–436.PubMedCrossRefGoogle Scholar
  44. 44.
    Bianchi ME. DAMPs, PAMPs and alarmins: all we need to know about danger. J. Leukoc. Biol 2007;81:1–5.PubMedCrossRefGoogle Scholar
  45. 45.
    Bonaldi T, Talamo F, Scaffidi P, Ferrera D, Porto A, Bachi A, et al. Monocytic cells hyperacetylate chromatin protein HMGB1 to redirect it towards secretion. EMBO J 2003;22:5551–5560.PubMedCrossRefGoogle Scholar
  46. 46.
    Wang H, Yang H, Tracey KJ. Extracellular role of HMGB1 in inflammation and sepsis. J Intern Med 2004;255:320–331.PubMedCrossRefGoogle Scholar
  47. 47.
    Abraham E, Arcaroli J, Carmody A, Wang H, Tracey KJ. HMG-1 as a mediator of acute lung inflammation. J Immunol 2000;165:2950–2954.PubMedGoogle Scholar
  48. 48.
    Kim JY, Park JS, Strassheim D, Douglas I, Diaz del Valle F, Asehnoune K, et al. HMGB1 contributes to the development of acute lung injury after hemorrhage. Am J Physiol Lung Cell Mol Physiol 2005;288:L958–965.PubMedCrossRefGoogle Scholar
  49. 49.
    Tsung A, Sahai R, Tanaka H, Nakao A, Fink MP, Lotze MT, et al. The nuclear factor HMGB1 mediates hepatic injury after murine liver ischemia-reperfusion. J Exp Med 2005;201:1135–1143.PubMedCrossRefGoogle Scholar
  50. 50.
    Wang H, Bloom O, Zhang M, Vishnubhakat JM, Ombrellino M, Che J, et al. HMG-1 as a late mediator of endotoxin lethality in mice. Science 1999;285(5425):248–251.PubMedCrossRefGoogle Scholar
  51. 51.
    Ombrellino M, Wang H, Ajemian MS, Talhouk A, Scher LA, Friedman SG, et al. Increased serum concentrations of high-mobility-group protein 1 in haemorrhagic shock. Lancet 1999;354(9188):1446–1447.PubMedCrossRefGoogle Scholar
  52. 52.
    Ueno H, Matsuda T, Hashimoto S, Amaya F, Kitamura Y, Tanaka M, et al. Contributions of high mobility group box protein in experimental and clinical acute lung injury. Am J Respir Crit Care Med 2004;170:1310–1316.PubMedCrossRefGoogle Scholar
  53. 53.
    Sundén-Cullberg J, Norrby-Teglund A, Rouhiainen A, Rauvala H, Herman G, Tracey KJ, et al. Persistent elevation of high mobility group box-1 protein (HMGB1) in patients with severe sepsis and septic shock. Crit Care Med 2005;33:564–573.PubMedCrossRefGoogle Scholar
  54. 54.
    Chen W, Syldath U, Bellmann K, Burkart V, Kolb H. Human 60-kDa heat-shock protein: a danger signal to the innate immune system. J Immunol 1999;162:3212–3219.PubMedGoogle Scholar
  55. 55.
    Ohashi K, Burkart V, Flohe S, Kolb H. Cutting edge: heat shock protein 60 is a putative endogenous ligand of the toll-like receptor-4 complex. J Immunol 2000;164:558–561.PubMedGoogle Scholar
  56. 56.
    Dybdahl B, Wahba A, Lien E, Flo TH, Waage A, Qureshi N, et al. Inflammatory response after open heart surgery: release of heat-shock protein 70 and signaling through toll-like receptor-4. Circulation 2002;105:685–690.PubMedCrossRefGoogle Scholar
  57. 57.
    Kimura F, Itoh H, Ambiru S, Shimizu H, Togawa A, Yoshidome H, et al. Circulating heat-shock protein 70 is associated with postoperative infection and organ dysfunction after liver resection. Am J Surg 2004;187:777–784.PubMedCrossRefGoogle Scholar
  58. 58.
    Bours MJ, Swennen EL, Di Virgilio F, Cronstein BN, Dagnelie PC. Adenosine 5′-triphosphate and adenosine as endogenous signaling molecules in immunity and inflammation. Pharmacol Ther 2006;112:358–404.PubMedCrossRefGoogle Scholar
  59. 59.
    Sitkovsky MV, Ohta A. The “danger” sensors that STOP the immune response: the A2 adenosine receptors? Trends Immunol 2005;26:299–304.PubMedCrossRefGoogle Scholar
  60. 60.
    Deaglio S, Dwyer KM, Gao W, Friedman D, Usheva A, Erat A, et al. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med 2007;204:1257–1265.PubMedCrossRefGoogle Scholar
  61. 61.
    van Maren WW, Jacobs JF, de Vries IJ, Nierkens S, Adema GJ. Toll-like receptor signalling on Tregs: to suppress or not to suppress? Immunology 2008;124:445–452.PubMedCrossRefGoogle Scholar
  62. 62.
    Seely AJ, Pascual JL, Christou NV. Science review: Cell membrane expression (connectivity) regulates neutrophil delivery, function and clearance. Crit Care 2003;7:291–307.PubMedCrossRefGoogle Scholar
  63. 63.
    Fialkow L, Wang Y, Downey GP. Reactive oxygen and nitrogen species as signaling molecules regulating neutrophil function. Free Radic Biol Med 2007;42:153–164.PubMedCrossRefGoogle Scholar
  64. 64.
    Wakefield CH, Carey PD, Foulds S, Monson JR, Guillou PJ. Polymorphonuclear leukocyte activation. An early marker of the postsurgical sepsis response. Arch Surg 1993;128:390–395.PubMedGoogle Scholar
  65. 65.
    Jimenez MF, Watson RW, Parodo J, Evans D, Foster D, Steinberg M, et al. Dysregulated expression of neutrophil apoptosis in the systemic inflammatory response syndrome. Arch Surg 1997;132:1263–1269.PubMedGoogle Scholar
  66. 66.
    Maekawa K, Futami S, Nishida M, Terada T, Inagawa H, Suzuki S, et al. Effects of trauma and sepsis on soluble L-selectin and cell surface expression of L-selectin and CD11b. J Trauma 1998;44:460–468.PubMedCrossRefGoogle Scholar
  67. 67.
    Quaid G, Cave C, Williams MA, Hennigan RF, Bokoch G, Solomkin JS. Mechanisms of human neutrophil oxidant production after severe injury. Surgery 2001;130:669–675.PubMedCrossRefGoogle Scholar
  68. 68.
    Foulds S, Mireskandari M, Kalu P, Jackson W, Cheshire NJ, Mansfield AO, et al. Visceral ischemia and neutrophil activation in sepsis and organ dysfunction. J Surg Res 1998;75:170–176.PubMedCrossRefGoogle Scholar
  69. 69.
    Foulds S, Cheshire NJ, Schachter M, Wolfe JH, Mansfield AO. Endotoxin related early neutrophil activation is associated with outcome after thoracoabdominal aortic aneurysm repair. Br J Surg 1997;84:172–177.PubMedCrossRefGoogle Scholar
  70. 70.
    Partrick DA, Moore EE, Fullerton DA, Barnett CC Jr, Meldrum DR, Silliman CC. Cardiopulmonary bypass renders patients at risk for multiple organ failure via early neutrophil priming and late neutrophil disability. J Surg Res 1999;86:42–49.PubMedCrossRefGoogle Scholar
  71. 71.
    Bhatia R, Dent C, Topley N, Pallister I. Neutrophil priming for elastase release in adult blunt trauma patients. J Trauma 2006;60:590–596.PubMedCrossRefGoogle Scholar
  72. 72.
    Gando S, Kameue T, Matsuda N, Sawamura A, Hayakawa M, Kato H. Systemic inflammation and disseminated intravascular coagulation in early stage of ALI and ARDS: role of neutrophil and endothelial activation. Inflammation 2004;28:237–244.PubMedCrossRefGoogle Scholar
  73. 73.
    Inoue Y, Tanaka H, Ogura H, Ukai I, Fujita K, Hosotsubo H, et al. A neutrophil elastase inhibitor, sivelestat, improves leukocyte deformability in patients with acute lung injury. J Trauma 2006;60:936–943.PubMedCrossRefGoogle Scholar
  74. 74.
    Gando S, Kameue T, Matsuda N, Hayakawa M, Ishitani T, Morimoto Y, et al. Combined activation of coagulation and inflammation has an important role in multiple organ dysfunction and poor outcome after severe trauma. Thromb Haemost 2002;88:943–949.PubMedGoogle Scholar
  75. 75.
    Rittirsch D, Flierl MA, Ward PA. Harmful molecular mechanisms in sepsis. Nat Rev Immunol 2008;8:776–787.PubMedCrossRefGoogle Scholar
  76. 76.
    Olson TS, Ley K. Chemokines and chemokine receptors in leukocyte trafficking. Am J Physiol Regul Integr Comp Physiol 2002;283:R7–28.PubMedGoogle Scholar
  77. 77.
    Reutershan J, Ley K. Bench-to-bedside review: acute respiratory distress syndrome—how neutrophils migrate into the lung. Crit Care 2004;8:453–461.PubMedCrossRefGoogle Scholar
  78. 78.
    Villard J, Dayer-Pastore F, Hamacher J, Aubert JD, Schlegel-Haueter S, Nicod LP. GRO alpha and interleukin-8 in Pneumocystis carinii or bacterial pneumonia and adult respiratory distress syndrome. Am J Respir Crit Care Med 1995;152:1549–1554.PubMedGoogle Scholar
  79. 79.
    Tsai WC, Strieter RM, Mehrad B, Newstead MW, Zeng X, Standiford TJ. CXC chemokine receptor CXCR2 is essential for protective innate host response in murine Pseudomonas aeruginosa pneumonia. Infect Immun 2000;68:4289–4296.PubMedCrossRefGoogle Scholar
  80. 80.
    Adams JM, Hauser CJ, Livingston DH, Lavery RF, Fekete Z, Deitch EA. Early trauma polymorphonuclear neutrophil responses to chemokines are associated with development of sepsis, pneumonia, and organ failure. J Trauma 2001;51:452–456.PubMedCrossRefGoogle Scholar
  81. 81.
    Tarlowe MH, Duffy A, Kannan KB, Itagaki K, Lavery RF, Livingston DH, et al. Prospective study of neutrophil chemokine responses in trauma patients at risk for pneumonia. Am J Respir Crit Care Med 2005;171:753–759.PubMedCrossRefGoogle Scholar
  82. 82.
    Brown KA, Brain SD, Pearson JD, Edgeworth JD, Lewis SM, Treacher DF. Neutrophils in development of multiple organ failure in sepsis. Lancet 2006;368(9530):157–169.PubMedCrossRefGoogle Scholar
  83. 83.
    Terregino CA, Lubkin CL, Thom SR. Impaired neutrophil adherence as an early marker of systemic inflammatory response syndrome and severe sepsis. Ann Emerg Med 1997;29:400–403.PubMedCrossRefGoogle Scholar
  84. 84.
    Arraes SM, Freitas MS, da Silva SV, de Paula Neto HA, Alves-Filho JC, Auxiliadora Martins M, et al. Impaired neutrophil chemotaxis in sepsis associates with GRK expression and inhibition of actin assembly and tyrosine phosphorylation. Blood 2006;108:2906–29013.PubMedCrossRefGoogle Scholar
  85. 85.
    Rot A, von Andrian UH. Chemokines in innate and adaptive host defense: basic chemokinese grammar for immune cells. Annu Rev Immunol 2004;22:891–928.PubMedCrossRefGoogle Scholar
  86. 86.
    Martins PS, Kallas EG, Neto MC, Dalboni MA, Blecher S, Salomão R. Upregulation of reactive oxygen species generation and phagocytosis, and increased apoptosis in human neutrophils during severe sepsis and septic shock. Shock 2003;20:208–212.PubMedCrossRefGoogle Scholar
  87. 87.
    Kaufmann I, Hoelzl A, Schliephake F, Hummel T, Chouker A, Peter K, et al. Polymorphonuclear leukocyte dysfunction syndrome in patients with increasing sepsis severity. Shock 2006;26:254–261.PubMedCrossRefGoogle Scholar
  88. 88.
    Danikas DD, Karakantza M, Theodorou GL, Sakellaropoulos GC, Gogos CA. Prognostic value of phagocytic activity of neutrophils and monocytes in sepsis. Correlation to CD64 and CD14 antigen expression. Clin Exp Immunol 2008;154:87–97.PubMedCrossRefGoogle Scholar
  89. 89.
    van der Meer W, Pickkers P, Scott CS, van der Hoeven JG, Gunnewiek JK. Hematological indices, inflammatory markers and neutrophil CD64 expression: comparative trends during experimental human endotoxemia. J Endotoxin Res 2007;13:94–100.PubMedCrossRefGoogle Scholar
  90. 90.
    Taneja R, Sharma AP, Hallett MB, Findlay GP, Morris MR. Immature circulating neutrophils in sepsis have impaired phagocytosis and calcium signaling. Shock 2008;30:618–622.PubMedCrossRefGoogle Scholar
  91. 91.
    Serbina NV, Jia T, Hohl TM, Pamer EG. Monocyte-mediated defense against microbial pathogens. Annu Rev Immunol 2008;26:421–452.PubMedCrossRefGoogle Scholar
  92. 92.
    Gordon S, Taylor PR. Monocyte and macrophage heterogeneity. Nat Rev Immunol 2005;5:953–964.PubMedCrossRefGoogle Scholar
  93. 93.
    Benoit M, Desnues B, Mege JL. Macrophage polarization in bacterial infections. J Immunol 2008;181:3733–3739.PubMedGoogle Scholar
  94. 94.
    Mosser DM, Edwards JP. Exploring the full spectrum of macrophage activation. Nat Rev Immunol 2008;8:958–969.PubMedCrossRefGoogle Scholar
  95. 95.
    Gerber JS, Mosser DM. Reversing lipopolysaccharide toxicity by ligating the macrophage Fc? receptors. J Immunol 2001;166:6861–6868.PubMedGoogle Scholar
  96. 96.
    Spolarics Z, Siddiqi M, Siegel JH, Garcia ZC, Stein DS, Denny T, et al. Depressed interleukin-12-producing activity by monocytes correlates with adverse clinical course and a shift toward Th2-type lymphocyte pattern in severely injured male trauma patients. Crit Care Med 2003;31:1722–1729.PubMedCrossRefGoogle Scholar
  97. 97.
    Weighardt H, Heidecke CD, Westerholt A, Emmanuilidis K, Maier S, Veit M, et al. Impaired monocyte IL-12 production before surgery as a predictive factor for the lethal outcome of postoperative sepsis. Ann Surg 2002;235:560–567.PubMedCrossRefGoogle Scholar
  98. 98.
    Ditschkowski M, Kreuzfelder E, Rebmann V, Ferencik S, Majetschak M, Schmid EN, et al. HLA-DR expression and soluble HLA-DR levels in septic patients after trauma. Ann Surg 1999;229:246–254.PubMedCrossRefGoogle Scholar
  99. 99.
    Wakefield CH, Carey PD, Foulds S, Monson JR, Guillou PJ. Changes in major histocompatibility complex class II expression in monocytes and T cells of patients developing infection after surgery. Br J Surg 1993;80:205–209.PubMedCrossRefGoogle Scholar
  100. 100.
    Schinkel C, Sendtner R, Zimmer S, Faist E. Functional analysis of monocyte subsets in surgical sepsis. J Trauma 1998;44:743–748.PubMedCrossRefGoogle Scholar
  101. 101.
    Venet F, Tissot S, Debard AL, Faudot C, Crampé C, Pachot A, et al. Decreased monocyte human leukocyte antigen-DR expression after severe burn injury: Correlation with severity and secondary septic shock. Crit Care Med 2007;35:1910–1917.PubMedCrossRefGoogle Scholar
  102. 102.
    Tschaikowsky K, Hedwig-Geissing M, Schiele A, Bremer F, Schywalsky M, Schüttler J. Coincidence of pro- and anti-inflammatory responses in the early phase of severe sepsis: Longitudinal study of mononuclear histocompatibility leukocyte antigen-DR expression, procalcitonin, C-reactive protein, and changes in T-cell subsets in septic and postoperative patients. Crit Care Med 2002;30:1015.PubMedCrossRefGoogle Scholar
  103. 103.
    Monneret G, Finck ME, Venet F, Debard AL, Bohé J, Bienvenu J, et al. The anti-inflammatory response dominates after septic shock: Association of low monocyte HLA-DR expression and high interleukin-10 concentration. Immunol Lett 2004;95:193–198.PubMedCrossRefGoogle Scholar
  104. 104.
    Fumeaux T, Pugin J. Role of interleukin-10 in the intracellular sequestration of human leukocyte antigen-DR in monocytes during septic shock. Am J Respir Crit Care Med 2002;166:1475–1482.PubMedCrossRefGoogle Scholar
  105. 105.
    Lekkou A, Karakantza M, Mouzaki A, Kalfarentzos F, Gogos CA. Cytokine production and monocyte HLA-DR expression as predictors of outcome for patients with community-acquired severe infections. Clin Diagn Lab Immunol 2004;11:161–167.PubMedGoogle Scholar
  106. 106.
    Abe R, Hirasawa H, Oda S, Sadahiro T, Nakamura M, Watanabe E, et al. Up-regulation of interleukin-10 mRNA expression in peripheral leukocytes predicts poor outcome and diminished human leukocyte antigen-DR expression on monocytes in septic patients. J Surg Res 2008;147:1–8.PubMedCrossRefGoogle Scholar
  107. 107.
    de Waal Malefyt R, Haanen J, Spits H, Roncarolo MG, te Velde A, Figdor C, et al. Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via down-regulation of class II major histocompatibility complex expression. J Exp Med 1991;174:915.PubMedCrossRefGoogle Scholar
  108. 108.
    Morel AS, Coulton G, Londei M. Regulation of major histocompatibility complex class II synthesis by interleukin-10. Immunology 2002;106:229–236.PubMedCrossRefGoogle Scholar
  109. 109.
    Aste-Amezaga M, Ma X, Sartori A, Trinchieri G. Molecular mechanisms of the induction of IL-12 and its inhibition by IL-10. J Immunol 1998;160:5936–5944.PubMedGoogle Scholar
  110. 110.
    Randow F, Syrbe U, Meisel C, Krausch D, Zuckermann H, Platzer C, et al. Mechanism of endotoxin desensitization: involvement of interleukin 10 and transforming growth factor beta. J Exp Med 1995;181:1887–1892.PubMedCrossRefGoogle Scholar
  111. 111.
    Döcke WD, Randow F, Syrbe U, Krausch D, Asadullah K, Reinke P, et al. Monocyte deactivation in septic patients: restoration by IFN-gamma treatment. Nat Med 1997;3:678–681.PubMedCrossRefGoogle Scholar
  112. 112.
    Astiz M, Saha D, Lustbader D, Lin R, Rackow E. Monocyte response to bacterial toxins, expression of cell surface receptors, and release of anti-inflammatory cytokines during sepsis. J Lab Clin Med 1996;128:594–600.PubMedCrossRefGoogle Scholar
  113. 113.
    Sfeir T, Saha DC, Astiz M, Rackow EC. Role of interleukin-10 in monocyte hyporesponsiveness associated with septic shock. Crit Care Med 2001;29:129–133.PubMedCrossRefGoogle Scholar
  114. 114.
    Tsujimoto H, Ono S, Majima T, Efron PA, Kinoshita M, Hiraide H, et al. Differential toll-like receptor expression after ex vivo lipopolysaccharide exposure in patients with sepsis and following surgical stress. Clin Immunol 2006;119:180–187.PubMedCrossRefGoogle Scholar
  115. 115.
    Schaaf B, Luitjens K, Goldmann T, van Bremen T, Sayk F, Dodt C, et al. Mortality in human sepsis is associated with downregulation of Toll-like receptor 2 and CD14 expression on blood monocytes. Diagn Pathol 2009;4:12.PubMedCrossRefGoogle Scholar
  116. 116.
    Re F, Strominger JL. IL-10 Released by concomitant TLR2 stimulation blocks the induction of a subset of Th1 cytokines that are specifically induced by TLR4 or TLR3 in human dendritic cells. J Immunol 2004;173:7548–7555.PubMedGoogle Scholar
  117. 117.
    Tamandl D, Bahrami M, Wessner B, Weigel G, Ploder M, Furst W, et al. Modulation of toll-like receptor 4 expression on human monocytes by tumor necrosis factor and interleukin-6: tumor necrosis factor evokes lipopolysaccharide hyporesponsiveness, whereas interleukin-6 enhances lipopolysaccharide activity. Shock 2003;20:224–229.PubMedCrossRefGoogle Scholar
  118. 118.
    Salomao R, Brunialti MK, Gomes NE, Mendes ME, Diaz RS, Komninakis S, et al. Toll-like receptor pathway signaling is differently regulated in neutrophils and peripheral mononuclear cells of patients with sepsis, severe sepsis, and septic shock. Crit Care Med 2009;37:132–139.PubMedCrossRefGoogle Scholar
  119. 119.
    Martins PS, Brunialti MK, Martos LS, Machado FR, Assunçao MS, Blecher S, et al. Expression of cell surface receptors and oxidative metabolism modulation in the clinical continuum of sepsis. Crit Care 2008;12:R25.PubMedCrossRefGoogle Scholar
  120. 120.
    Zughaier SM, Shafer WM, Stephens DS. Antimicrobial peptides and endotoxin inhibit cytokine and nitric oxide release but amplify respiratory burst response in human and murine macrophages. Cell Microbiol 2005;7:1251–1262.PubMedCrossRefGoogle Scholar
  121. 121.
    Wolkow PP. Involvement and dual effects of nitric oxide in septic shock. Inflamm Res 1998;47(4):152–166.PubMedCrossRefGoogle Scholar
  122. 122.
    Cauwels A, Brouckaert P. Survival of TNF toxicity: dependence on caspases and NO. Arch Biochem Biophys 2007;462:132–139.PubMedCrossRefGoogle Scholar
  123. 123.
    Bultinck J, Sips P, Vakaet L, Brouckaert P, Cauwels A. Systemic NO production during (septic) shock depends on parenchymal and not on hematopoietic cells: in vivo iNOS expression pattern in (septic) shock. FASEB J 2006;20:2363–2365.PubMedCrossRefGoogle Scholar
  124. 124.
    Annane D, Sanquer S, Sébille V, Faye A, Djuranovic D, Raphaël JC, et al. Compartmentalised inducible nitric-oxide synthase activity in septic shock. Lancet 2000;355(9210):1143–1148.PubMedCrossRefGoogle Scholar
  125. 125.
    Hirabayashi N, Tanimura H, Yamaue H. Nitrite/nitrate oxide and cytokines changes in patients with surgical stress. Dig Dis Sci 2005;50:893–897.PubMedCrossRefGoogle Scholar
  126. 126.
    Novotny AR, Emmanuel K, Maier S, Westerholt A, Weighardt H, Stadler J, et al. Cytochrome P450 activity mirrors nitric oxide levels in postoperative sepsis: predictive indicators of lethal outcome. Surgery 2007;141:376–384.PubMedCrossRefGoogle Scholar
  127. 127.
    Kobayashi A, Hashimoto S, Kooguchi K, Kitamura Y, Onodera H, Urata Y, et al. Expression of inducible nitric oxide synthase and inflammatory cytokines in alveolar macrophages of ARDS following sepsis. Chest 1998;113:1632–1639.PubMedCrossRefGoogle Scholar
  128. 128.
    Tsukahara Y, Morisaki T, Horita Y, Torisu M, Tanaka M. Expression of inducible nitric oxide synthase in circulating neutrophils of the systemic inflammatory response syndrome and septic patients. World J Surg 1998;22:771–777.PubMedCrossRefGoogle Scholar
  129. 129.
    Weinberg JB, Misukonis MA, Shami PJ, Mason SN, Sauls DL, Dittman WA, et al. Human mononuclear phagocyte inducible nitric oxide synthase (iNOS): analysis of iNOS mRNA, iNOS protein, biopterin, and nitric oxide production by blood monocytes and peritoneal macrophages. Blood 1995;86:1184–1195.PubMedGoogle Scholar
  130. 130.
    Tashiro T, Yamamori H, Takagi K, Hayashi N, Furukawa K, Nitta H, et al. Changes in immune function following surgery for esophageal carcinoma. Nutrition 1999;15:760–766.PubMedCrossRefGoogle Scholar
  131. 131.
    Faist E, Kupper TS, Baker CC, Chaudry IH, Dwyer J, Baue AE. Depression of cellular immunity after major injury. Its association with posttraumatic complications and its reversal with immunomodulation. Arch Surg 1986;121:1000–1005.PubMedGoogle Scholar
  132. 132.
    O’Mahony JB, Palder SB, Wood JJ, McIrvine A, Rodrick ML, Demling RH, et al. Depression of cellular immunity after multiple trauma in the absence of sepsis. J Trauma 1984;24:869–875.PubMedCrossRefGoogle Scholar
  133. 133.
    McIrvine AJ, O’Mahony JB, Saporoschetz I, Mannick JA. Depressed immune response in burn patients: use of monoclonal antibodies and functional assays to define the role of suppressor cells. Ann Surg 1982;196:297–304.PubMedCrossRefGoogle Scholar
  134. 134.
    Mosmann TR, Cherwinski H, Bond MW, Giedlin MA, Coffman RL. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 1986;136:2348–2357.PubMedGoogle Scholar
  135. 135.
    Decker D, Schondorf M, Bidlingmaier F, Hirner A, von Ruecker AA. Surgical stress induces a shift in the type-1/type-2 T-helper cell balance, suggesting down-regulation of cell-mediated and up-regulation of antibody-mediated immunity commensurate to the trauma. Surgery 1996;119:316–325.PubMedCrossRefGoogle Scholar
  136. 136.
    Heidecke CD, Hensler T, Weighardt H, Zantl N, Wagner H, Siewert JR, et al. Selective defects of T lymphocyte function in patients with lethal intra-abdominal infection. Am J Surg 1999;178:288–292.PubMedCrossRefGoogle Scholar
  137. 137.
    Zedler S, Bone RC, Baue AE, von Donnersmarck GH, Faist E. T-cell reactivity and its predictive role in immunosuppression after burns. Crit Care Med 1999;27:66–72.PubMedCrossRefGoogle Scholar
  138. 138.
    Kidd P. Th1/Th2 balance: the hypothesis, its limitations, and implications for health and disease. Altern Med Rev 2003;8:223–246.PubMedGoogle Scholar
  139. 139.
    Hwang ES, Szabo SJ, Schwartzberg PL, Glimcher LH. T helper cell fate specified by kinase-mediated interaction of T-bet with GATA-3. Science 2005;307:430–433.PubMedCrossRefGoogle Scholar
  140. 140.
    Miller AC, Rashid RM, Elamin EM. The “Tr” in trauma: the helper T-cell response and the role of immunomodulation in trauma and burn patients. J Trauma 2007;63:1407–1417.PubMedCrossRefGoogle Scholar
  141. 141.
    O’Garra A, Arai N. The molecular basis of T helper 1 and T helper 2 cell differentiation. Trends Cell Biol 2000;10:542–550.PubMedCrossRefGoogle Scholar
  142. 142.
    O’suilleabhain C, O’sullivan ST, Kelly JL, Lederer J, Mannick JA, Rodrick ML. Interleukin-12 treatment restores normal resistance to bacterial challenge after burn injury. Surgery 1996;120:290–296.PubMedCrossRefGoogle Scholar
  143. 143.
    Hensler T, Heidecke CD, Hecker H, Heeg K, Bartels H, Zantl N, et al. Increased susceptibility to postoperative sepsis in patients with impaired monocyte IL-12 production. J Immunol 1998;161:2655–2659.PubMedGoogle Scholar
  144. 144.
    Afzali B, Lombardi G, Lechler RI, Lord GM. The role of T helper 17 (Th17) and regulatory T cells (Treg) in human organ transplantation and autoimmune disease. Clin Exp Immunol 2007;148:32–46.PubMedCrossRefGoogle Scholar
  145. 145.
    Mills KH. Induction, function and regulation of IL-17-producing T cells. Eur J Immunol 2008;38:2636–2649.PubMedCrossRefGoogle Scholar
  146. 146.
    Chen Z, O’shea JJ. Th17 cells: a new fate for differentiating helper T cells. Immunol Res 2008;41:87–102.PubMedCrossRefGoogle Scholar
  147. 147.
    Saruta M, Yu QT, Fleshner PR, Mantel PY, Schmidt-Weber CB, Banham AH, et al. Characterization of FOXP3+CD4+ regulatory T cells in Crohn’s disease. Clin Immunol 2007;125:281–290.PubMedCrossRefGoogle Scholar
  148. 148.
    Xu D, Fu J, Jin L, Zhang H, Zhou C, Zou Z, et al. Circulating and liver resident CD4+CD25+ regulatory T cells actively influence the antiviral immune response and disease progression in patients with hepatitis B. J Immunol 2006;177:739–747.PubMedGoogle Scholar
  149. 149.
    MacConmara MP, Maung AA, Fujimi S, McKenna AM, Delisle A, Lapchak PH, et al. Increased CD4+ CD25+ T regulatory cell activity in trauma patients depresses protective Th1 immunity. Ann Surg 2006;244:514–523.PubMedGoogle Scholar
  150. 150.
    Tiemessen MM, Jagger AL, Evans HG, van Herwijnen MJ, John S, Taams LS. CD4+CD25+Foxp3+ regulatory T cells induce alternative activation of human monocytes/macrophages. Proc Natl Acad Sci USA 2007;104:19446–19451.PubMedCrossRefGoogle Scholar
  151. 151.
    Korn T, Anderson AC, Bettelli E, Oukka M. The dynamics of effector T cells and Foxp3+ regulatory T cells in the promotion and regulation of autoimmune encephalomyelitis. J Neuroimmunol 2007;191:51–60.PubMedCrossRefGoogle Scholar
  152. 152.
    Zheng Y, Danilenko DM, Valdez P, Kasman I, Eastham-Anderson J, Wu J, et al. Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature 2007;445(7128):648–651.PubMedCrossRefGoogle Scholar
  153. 153.
    Loong CC, Hsieh HG, Lui WY, Chen A, Lin CY. Evidence for the early involvement of interleukin 17 in human and experimental renal allograft rejection. J Pathol 2002;197:322–332.PubMedCrossRefGoogle Scholar
  154. 154.
    Fujino S, Andoh A, Bamba S, Ogawa A, Hata K, Araki Y, et al. Increased expression of interleukin 17 in inflammatory bowel disease. Gut 2003;52:65–70.PubMedCrossRefGoogle Scholar
  155. 155.
    Frangen TM, Bogdanski D, Schinkel C, Roetman B, Kälicke T, Muhr G, et al. Systemic IL-17 after severe injuries. Shock 2008;29(4):462–467.PubMedGoogle Scholar
  156. 156.
    Hotchkiss RS, Tinsley KW, Swanson PE, Schmieg RE Jr, Hui JJ, Chang KC, et al. Sepsis-induced apoptosis causes progressive profound depletion of B and CD4+ T lymphocytes in humans. J Immunol 2001;166:6952–6963.PubMedGoogle Scholar
  157. 157.
    Felmet KA, Hall MW, Clark RS, Jaffe R, Carcillo JA. Prolonged lymphopenia, lymphoid depletion, and hypoprolactinemia in children with nosocomial sepsis and multiple organ failure. J Immunol 2005;174:3765–3772.PubMedGoogle Scholar
  158. 158.
    Hotchkiss RS, Osmon SB, Chang KC, Wagner TH, Coopersmith CM, Karl IE. Accelerated lymphocyte death in sepsis occurs by both the death receptor and mitochondrial pathways. J Immunol 2005;174:5110–5118.PubMedGoogle Scholar
  159. 159.
    Wesche DE, Lomas-Neira JL, Perl M, Chung CS, Ayala A. Leukocyte apoptosis and its significance in sepsis and shock. J Leukoc Biol 2005;78:325–337.PubMedCrossRefGoogle Scholar
  160. 160.
    Hotchkiss RS, Nicholson DW. Apoptosis and caspases regulate death and inflammation in sepsis. Nat Rev Immunol 2006;6:813–822.PubMedCrossRefGoogle Scholar

Copyright information

© Springer 2010

Authors and Affiliations

  • Fumio Kimura
    • 1
  • Hiroaki Shimizu
    • 1
  • Hiroyuki Yoshidome
    • 1
  • Masayuki Ohtsuka
    • 1
  • Masaru Miyazaki
    • 1
  1. 1.Department of General SurgeryChiba University Graduate School of MedicineChibaJapan

Personalised recommendations